Consistent with the description of other studies, our data demonstrated no correlation between KRAS/GNAS mutations and tumor grade, and KRAS or GNAS mutation cases accounted for most of the IPMN cases (85%) in our cohort. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.